Concepts (207)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Wearable Electronic Devices | 7 | 2024 | 69 | 3.080 |
Why?
|
| Substance-Related Disorders | 8 | 2024 | 735 | 2.740 |
Why?
|
| Cannabis | 3 | 2023 | 51 | 2.140 |
Why?
|
| Telemedicine | 5 | 2024 | 330 | 2.030 |
Why?
|
| Opioid-Related Disorders | 10 | 2024 | 509 | 1.950 |
Why?
|
| Drug Overdose | 7 | 2025 | 131 | 1.650 |
Why?
|
| Craving | 3 | 2024 | 36 | 1.640 |
Why?
|
| Cannabinoids | 3 | 2023 | 41 | 1.620 |
Why?
|
| Analgesics, Opioid | 10 | 2024 | 536 | 1.550 |
Why?
|
| Substance Abuse Detection | 3 | 2016 | 45 | 1.400 |
Why?
|
| Fat Emulsions, Intravenous | 4 | 2015 | 37 | 1.350 |
Why?
|
| Acute Pain | 3 | 2024 | 21 | 1.140 |
Why?
|
| Biosensing Techniques | 5 | 2017 | 119 | 1.110 |
Why?
|
| Mobile Applications | 5 | 2024 | 137 | 1.110 |
Why?
|
| Stress, Psychological | 2 | 2024 | 474 | 1.100 |
Why?
|
| Seizures | 2 | 2025 | 143 | 1.030 |
Why?
|
| Cocaine | 4 | 2015 | 101 | 1.030 |
Why?
|
| Monitoring, Ambulatory | 3 | 2016 | 57 | 1.020 |
Why?
|
| Machine Learning | 4 | 2024 | 181 | 0.980 |
Why?
|
| Explosive Agents | 1 | 2025 | 5 | 0.940 |
Why?
|
| Plastics | 1 | 2025 | 22 | 0.920 |
Why?
|
| Analgesics, Non-Narcotic | 2 | 2019 | 36 | 0.770 |
Why?
|
| Hallucinogens | 1 | 2022 | 14 | 0.750 |
Why?
|
| Smartphone | 4 | 2024 | 69 | 0.730 |
Why?
|
| Toxicology | 2 | 2024 | 33 | 0.730 |
Why?
|
| Circulating MicroRNA | 1 | 2019 | 6 | 0.640 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2019 | 53 | 0.610 |
Why?
|
| Acetaminophen | 1 | 2019 | 58 | 0.600 |
Why?
|
| Humans | 36 | 2025 | 63533 | 0.570 |
Why?
|
| Systems Integration | 1 | 2017 | 26 | 0.530 |
Why?
|
| Glass | 1 | 2017 | 23 | 0.530 |
Why?
|
| Male | 23 | 2025 | 29937 | 0.520 |
Why?
|
| Transducers | 1 | 2017 | 26 | 0.520 |
Why?
|
| Emergency Service, Hospital | 9 | 2024 | 1105 | 0.520 |
Why?
|
| Adult | 15 | 2025 | 16895 | 0.500 |
Why?
|
| Transcriptome | 1 | 2019 | 386 | 0.490 |
Why?
|
| Hemodynamics | 2 | 2013 | 248 | 0.470 |
Why?
|
| Secondary Prevention | 1 | 2016 | 164 | 0.470 |
Why?
|
| Cocaine-Related Disorders | 1 | 2015 | 82 | 0.460 |
Why?
|
| Social Media | 1 | 2017 | 125 | 0.450 |
Why?
|
| Research Design | 1 | 2017 | 575 | 0.420 |
Why?
|
| Pilot Projects | 7 | 2021 | 1015 | 0.410 |
Why?
|
| Advanced Cardiac Life Support | 1 | 2013 | 14 | 0.410 |
Why?
|
| Epinephrine | 1 | 2013 | 46 | 0.410 |
Why?
|
| Vasoconstrictor Agents | 1 | 2013 | 70 | 0.400 |
Why?
|
| Young Adult | 5 | 2025 | 4713 | 0.390 |
Why?
|
| Naloxone | 3 | 2023 | 61 | 0.370 |
Why?
|
| Disease Models, Animal | 3 | 2013 | 2196 | 0.370 |
Why?
|
| Skin | 1 | 2015 | 374 | 0.370 |
Why?
|
| Galvanic Skin Response | 3 | 2016 | 24 | 0.360 |
Why?
|
| Cardiovascular Diseases | 1 | 2019 | 844 | 0.360 |
Why?
|
| Female | 17 | 2025 | 32945 | 0.340 |
Why?
|
| Biomedical Research | 3 | 2024 | 269 | 0.340 |
Why?
|
| Middle Aged | 9 | 2024 | 17659 | 0.330 |
Why?
|
| Heart Rate | 3 | 2020 | 322 | 0.320 |
Why?
|
| Buprenorphine | 2 | 2023 | 193 | 0.320 |
Why?
|
| Narcotic Antagonists | 3 | 2021 | 137 | 0.320 |
Why?
|
| Financing, Government | 2 | 2020 | 31 | 0.320 |
Why?
|
| Pain Management | 2 | 2024 | 163 | 0.310 |
Why?
|
| Emergency Medicine | 2 | 2020 | 190 | 0.270 |
Why?
|
| Oxycodone | 2 | 2017 | 30 | 0.260 |
Why?
|
| Faculty, Medical | 2 | 2019 | 196 | 0.260 |
Why?
|
| Harm Reduction | 2 | 2025 | 33 | 0.260 |
Why?
|
| Child | 3 | 2022 | 4541 | 0.260 |
Why?
|
| Biomarkers | 2 | 2024 | 1406 | 0.260 |
Why?
|
| Logistic Models | 2 | 2021 | 1267 | 0.260 |
Why?
|
| Skin Temperature | 2 | 2016 | 19 | 0.250 |
Why?
|
| Fractures, Bone | 2 | 2017 | 143 | 0.240 |
Why?
|
| Wrist | 2 | 2016 | 39 | 0.240 |
Why?
|
| Self Report | 2 | 2020 | 381 | 0.230 |
Why?
|
| Rats, Sprague-Dawley | 4 | 2013 | 620 | 0.230 |
Why?
|
| Adolescent | 3 | 2021 | 6258 | 0.230 |
Why?
|
| Benzodiazepines | 1 | 2025 | 100 | 0.220 |
Why?
|
| Anticonvulsants | 1 | 2025 | 104 | 0.220 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2016 | 866 | 0.220 |
Why?
|
| Sentinel Surveillance | 1 | 2024 | 19 | 0.210 |
Why?
|
| Terminology as Topic | 1 | 2025 | 140 | 0.210 |
Why?
|
| Military Personnel | 1 | 2025 | 120 | 0.210 |
Why?
|
| Dronabinol | 1 | 2023 | 32 | 0.210 |
Why?
|
| Chromatography, Liquid | 1 | 2023 | 131 | 0.200 |
Why?
|
| Random Allocation | 2 | 2013 | 199 | 0.200 |
Why?
|
| Reproducibility of Results | 3 | 2024 | 1665 | 0.200 |
Why?
|
| Rats | 4 | 2013 | 1991 | 0.200 |
Why?
|
| Treatment Outcome | 3 | 2025 | 5630 | 0.200 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2023 | 147 | 0.200 |
Why?
|
| Psychometrics | 1 | 2024 | 384 | 0.190 |
Why?
|
| Research Support as Topic | 2 | 2019 | 42 | 0.190 |
Why?
|
| National Institutes of Health (U.S.) | 2 | 2020 | 119 | 0.190 |
Why?
|
| Cannabinoid Receptor Agonists | 1 | 2022 | 8 | 0.190 |
Why?
|
| Mentors | 2 | 2020 | 121 | 0.180 |
Why?
|
| Cholinergic Antagonists | 2 | 2019 | 32 | 0.180 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2023 | 123 | 0.180 |
Why?
|
| Tertiary Healthcare | 1 | 2021 | 15 | 0.180 |
Why?
|
| Blood Pressure | 2 | 2013 | 514 | 0.170 |
Why?
|
| Aged | 5 | 2024 | 14457 | 0.170 |
Why?
|
| Decision Making | 1 | 2024 | 411 | 0.170 |
Why?
|
| Longitudinal Studies | 1 | 2024 | 1259 | 0.170 |
Why?
|
| Drug Users | 1 | 2021 | 28 | 0.170 |
Why?
|
| Eating | 1 | 2021 | 139 | 0.160 |
Why?
|
| Geographic Information Systems | 1 | 2020 | 24 | 0.160 |
Why?
|
| Wireless Technology | 1 | 2020 | 18 | 0.160 |
Why?
|
| Time Factors | 2 | 2019 | 3710 | 0.150 |
Why?
|
| Cardiotonic Agents | 1 | 2019 | 54 | 0.150 |
Why?
|
| Research Personnel | 1 | 2020 | 94 | 0.150 |
Why?
|
| Medication Adherence | 2 | 2017 | 204 | 0.150 |
Why?
|
| Hypnotics and Sedatives | 1 | 2019 | 66 | 0.150 |
Why?
|
| United States | 5 | 2024 | 7837 | 0.150 |
Why?
|
| Mindfulness | 1 | 2020 | 70 | 0.150 |
Why?
|
| Combined Modality Therapy | 2 | 2017 | 375 | 0.150 |
Why?
|
| Efficiency | 1 | 2018 | 41 | 0.140 |
Why?
|
| Naltrexone | 1 | 2019 | 89 | 0.140 |
Why?
|
| Writing | 1 | 2018 | 44 | 0.140 |
Why?
|
| Medical Informatics Applications | 1 | 2017 | 14 | 0.140 |
Why?
|
| Antidepressive Agents | 1 | 2019 | 226 | 0.140 |
Why?
|
| Incidence | 1 | 2021 | 1374 | 0.130 |
Why?
|
| Telemetry | 1 | 2017 | 19 | 0.130 |
Why?
|
| Alcoholism | 1 | 2020 | 317 | 0.130 |
Why?
|
| Music Therapy | 1 | 2017 | 20 | 0.130 |
Why?
|
| Diffusion of Innovation | 1 | 2017 | 60 | 0.130 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 981 | 0.130 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 1092 | 0.130 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2017 | 98 | 0.130 |
Why?
|
| Prognosis | 1 | 2021 | 1744 | 0.130 |
Why?
|
| Administration, Intravenous | 1 | 2016 | 64 | 0.120 |
Why?
|
| Forecasting | 1 | 2017 | 233 | 0.120 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 769 | 0.120 |
Why?
|
| Equipment Design | 1 | 2017 | 357 | 0.120 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2016 | 78 | 0.120 |
Why?
|
| Pharmaceutical Preparations | 1 | 2017 | 123 | 0.120 |
Why?
|
| Motion | 1 | 2015 | 59 | 0.120 |
Why?
|
| Locomotion | 1 | 2016 | 116 | 0.120 |
Why?
|
| Registries | 1 | 2019 | 873 | 0.120 |
Why?
|
| Prospective Studies | 2 | 2020 | 3296 | 0.110 |
Why?
|
| Age Factors | 1 | 2019 | 1561 | 0.110 |
Why?
|
| Body Temperature | 1 | 2015 | 45 | 0.110 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 144 | 0.110 |
Why?
|
| Infant, Newborn | 1 | 2019 | 1363 | 0.110 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2020 | 485 | 0.110 |
Why?
|
| Chronic Pain | 1 | 2017 | 154 | 0.110 |
Why?
|
| Hospital Mortality | 1 | 2019 | 867 | 0.110 |
Why?
|
| Algorithms | 1 | 2020 | 1005 | 0.110 |
Why?
|
| Retrospective Studies | 3 | 2021 | 6620 | 0.110 |
Why?
|
| Infant | 1 | 2019 | 1654 | 0.110 |
Why?
|
| Pain | 1 | 2017 | 407 | 0.100 |
Why?
|
| Animals | 5 | 2015 | 20715 | 0.100 |
Why?
|
| Anticholinergic Syndrome | 1 | 2013 | 1 | 0.100 |
Why?
|
| beta-Alanine | 1 | 2013 | 8 | 0.100 |
Why?
|
| Child, Preschool | 1 | 2019 | 1999 | 0.100 |
Why?
|
| Atropine | 1 | 2013 | 13 | 0.100 |
Why?
|
| Sodium Chloride | 1 | 2013 | 63 | 0.100 |
Why?
|
| Antithrombins | 1 | 2013 | 15 | 0.100 |
Why?
|
| Parenteral Nutrition, Total | 1 | 2013 | 28 | 0.100 |
Why?
|
| Blood Coagulation | 1 | 2013 | 39 | 0.100 |
Why?
|
| Muscarinic Antagonists | 1 | 2013 | 33 | 0.100 |
Why?
|
| Benzimidazoles | 1 | 2013 | 54 | 0.100 |
Why?
|
| Feasibility Studies | 1 | 2015 | 570 | 0.100 |
Why?
|
| Cyclohexylamines | 1 | 2012 | 5 | 0.090 |
Why?
|
| Mitragyna | 1 | 2012 | 5 | 0.090 |
Why?
|
| Salvia | 1 | 2012 | 3 | 0.090 |
Why?
|
| Cyclohexanones | 1 | 2012 | 5 | 0.090 |
Why?
|
| Alkaloids | 1 | 2012 | 12 | 0.090 |
Why?
|
| Hemorrhage | 1 | 2013 | 265 | 0.090 |
Why?
|
| Kinetics | 1 | 2013 | 763 | 0.090 |
Why?
|
| Piperazines | 1 | 2012 | 81 | 0.090 |
Why?
|
| Survival Rate | 1 | 2013 | 853 | 0.090 |
Why?
|
| Psychotropic Drugs | 1 | 2012 | 84 | 0.090 |
Why?
|
| Electrocardiography | 1 | 2013 | 552 | 0.080 |
Why?
|
| Risk Factors | 1 | 2019 | 5284 | 0.080 |
Why?
|
| Massachusetts | 1 | 2015 | 2074 | 0.070 |
Why?
|
| Aged, 80 and over | 1 | 2015 | 5468 | 0.060 |
Why?
|
| Delphi Technique | 1 | 2025 | 101 | 0.060 |
Why?
|
| Surveys and Questionnaires | 2 | 2024 | 2704 | 0.050 |
Why?
|
| Fever | 1 | 2024 | 66 | 0.050 |
Why?
|
| Consensus | 1 | 2025 | 201 | 0.050 |
Why?
|
| Disease Outbreaks | 1 | 2024 | 115 | 0.050 |
Why?
|
| Buprenorphine, Naloxone Drug Combination | 1 | 2023 | 26 | 0.050 |
Why?
|
| Focus Groups | 1 | 2024 | 305 | 0.050 |
Why?
|
| Community Health Services | 1 | 2023 | 128 | 0.050 |
Why?
|
| Prescriptions | 1 | 2022 | 33 | 0.050 |
Why?
|
| Societies, Medical | 1 | 2024 | 378 | 0.050 |
Why?
|
| Hospitals | 1 | 2024 | 391 | 0.040 |
Why?
|
| Opiate Substitution Treatment | 1 | 2023 | 207 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2024 | 705 | 0.040 |
Why?
|
| Phenotype | 1 | 2024 | 1208 | 0.040 |
Why?
|
| Academies and Institutes | 1 | 2019 | 24 | 0.040 |
Why?
|
| Trauma Centers | 1 | 2019 | 125 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2020 | 487 | 0.030 |
Why?
|
| Capsules | 1 | 2017 | 35 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2019 | 315 | 0.030 |
Why?
|
| Pain Perception | 1 | 2017 | 7 | 0.030 |
Why?
|
| Pain Threshold | 1 | 2017 | 25 | 0.030 |
Why?
|
| Radio Waves | 1 | 2017 | 19 | 0.030 |
Why?
|
| Drug Approval | 1 | 2017 | 26 | 0.030 |
Why?
|
| Sex Factors | 1 | 2019 | 973 | 0.030 |
Why?
|
| Morbidity | 1 | 2017 | 112 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 2017 | 89 | 0.030 |
Why?
|
| Affect | 1 | 2017 | 127 | 0.030 |
Why?
|
| Pain Measurement | 1 | 2017 | 345 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2021 | 566 | 0.030 |
Why?
|
| Social Support | 1 | 2018 | 372 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2017 | 340 | 0.030 |
Why?
|
| Women's Health | 1 | 2017 | 371 | 0.030 |
Why?
|
| Bleeding Time | 1 | 2013 | 4 | 0.030 |
Why?
|
| Dabigatran | 1 | 2013 | 20 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2013 | 173 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2013 | 369 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 705 | 0.020 |
Why?
|